Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

VitaNova Life Sciences (YJGJ) EPS (Weighted Average and Diluted) (2017 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with $0.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 9.69% year-over-year to $0.0, compared with a TTM value of $0.03 through Oct 2025, up 200.0%, and an annual FY2025 reading of $0.03, up 200.0% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.0 for Q4 2025 at VitaNova Life Sciences, up from -$0.0 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.03 in Q2 2025 and bottomed at -$0.0 in Q2 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.0, with a median of $0.0 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 1236.22% in 2023, then skyrocketed 1438.94% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.0 in 2021, then crashed by 82.67% to $0.0 in 2022, then tumbled by 436.6% to -$0.0 in 2023, then skyrocketed by 187.53% to $0.0 in 2024, then rose by 9.69% to $0.0 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for YJGJ at $0.0 in Q4 2025, -$0.0 in Q3 2025, and $0.03 in Q2 2025.